

Edwards
SAPIEN 3 Ultra
RESILIA valve

The ultimate solution for your
lifetime management strategy


R E S L I A



Edwards


The SAPIEN 3 Ultra RESILIA valve

Effectively addressing calcification, a leading cause of tissue valve failure.



Advanced calcium-blocking tissue technology^{1,2}

Potential to improve valve longevity and reduce risk of reintervention



Taller*, textured outer skirt extended to 29mm valve¹

Delivering the PVL results you demand impacting immediate and long-term outcomes^{3,4}



Only THV with dry tissue storage¹

Mitigates calcium-attracting glutaraldehyde residuals

The SAPIEN 3 Ultra RESILIA valve represents the latest innovation on the SAPIEN TAVI* platform

* TAVI = Transcatheter Aortic Valve Implantation

SAPIEN 3 Ultra RESILIA valve

The right move now. Even better for what's next.

Life

Consistent outcomes that matter, starting with the index procedure

1% death and disabling stroke at 1 year⁵

Time

A comprehensive approach to a durable therapy that offers proven long-term patient outcomes

90% survival at 5 years⁶

Management

Making future options possible

Only valve with

THV-in-THV

indication⁷ and design to facilitate future interventions⁸

Powered by
RESILIA
tissue
technology


The **ultimate** lifetime management **solution** for all eligible patients

RESILIA tissue technology

A significant evolution with potential to improve valve longevity.

Calcification is a primary driver of SVD for aortic tissue valves⁹

RESILIA tissue's advanced proprietary calcium-blocking technology targets free aldehydes, a key factor in calcification.²



Free Aldehyde

Step 1

A small amine binds a free aldehyde to form an unstable Schiff base

Step 2

Stabilization of the unstable Schiff base to form a covalent bond

Result

Free aldehyde is stable-capped



Unique glycerolization process removes calcium-attracting gluteraldehyde residuals and allows for dry tissue storage, preventing further exposure to free aldehydes²


SVD = structural valve deterioration
NSVD = non-structural valve dysfunction

RESILIA tissue is part of a comprehensive approach to durability

The SAPIEN 3 Ultra RESILIA valve addresses key drivers of SVD and NSVD



Control Valve (6900P)




✓ RESILIA Tissue Valve

72%
lower calcium
content¹⁰

RESILIA tissue showed **significant improvement** in calcium-blocking properties*


Paravalvular leak is a primary driver of NSVD for aortic tissue valves.¹¹

Taller**, textured skirt technology to reduce PVL now available on 29 mm valve for larger-annulus patients.



*RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards Lifesciences in a juvenile sheep model.

**Compared to the SAPIEN 3 valve



SAPIEN 3 Ultra RESILIA valve

- Enhances potential durability with RESILIA tissue technology¹
- Benefits of the proven predictability and superior outcomes of the SAPIEN 3 platform^{5,6}
- Fully addresses the vital considerations for optimal lifetime management
 - Superior outcomes of the index procedure⁵
 - Durability that stands up to surgical aortic valve replacement⁶
 - Protects future treatment options⁸

† The COMMENCE trial evaluated performance of surgical aortic valves with RESILIA tissue

References

1. Data on file
2. De la Fuente et al. Advanced Integrity Preservation Technology Reduces Bioprosthesis Calcification While Preserving Performance and Safety. *Journal of Heart Valve Disease*. 2015.
3. Kodali S et al. Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards SAPIEN valve in the PARTNER trial: characterizing patients and impact on outcomes. *Eur Heart J*. 2015.
4. Makkar R et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med*. 2020.
5. Mack MJ et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med*. 2019.
6. Mack MJ et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. *N Engl J Med*. 2023
7. Tarantini G, et al. Redo-Transcatheter aortic valve implantation using the SAPIEN 3/Ultra transcatheter heart valves - Expert Consensus on Procedural Planning Techniques, *The American Journal of Cardiology*, 2023
8. Tarantini G et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. *Circ Cardiovasc Interv*. 2020.
9. Tod TJ et al. The association of bound aldehyde content with bioprosthetic tissue calcification. *J Mater Sci Mater Med*. 2016.
10. Flameng W, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. *J Thorac Cardiovasc Surg*. 2015.
11. Pibarot et al. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial. *J Am Coll Cardiol*. 2020 Oct 20;76(16):1830-1843.
12. Beaver T et al. Seven-Year Outcomes Following Aortic Valve Replacement with a Novel Tissue Bioprosthesis. *Journal of Thoracic and Cardiovascular Surgery*. 2023.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, PARTNER, RESILIA, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2024 Edwards Lifesciences Corporation. All rights reserved. PP--EU-9490 v1.0 / MDMA-2-2023-1731

Edwards Lifesciences Sàrl • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com



Edwards